We demonstrated that, in contrast to classical opioid receptors, ACKR3 would not induce classical G protein signaling and isn't modulated via the classical prescription or analgesic opioids, like morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists including naloxone. Alternatively, we founded that LIH383, an ACKR3-selective subnanomolar competitor peptide, https://marlboroughs678mjh6.ja-blog.com/profile